The primary objectives of this study are to evaluate the clinical responder rate, defined as
the proportion of subjects with normal UFC after 6 months of treatment with COR-003 in the
Maintenance Phase without dose increase, and to evaluate the range of effective doses in
subjects with various levels of hypercortisolism.